# A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

> **NCT06246513** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Limb-girdle Muscular Dystrophy

## Interventions

- **BIOLOGICAL:** SRP-9003
- **DRUG:** Glucocorticoid

## Key facts

- **NCT ID:** NCT06246513
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-15
- **Primary completion:** 2025-03-04
- **Final completion:** 2029-11-30
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06246513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06246513, "A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06246513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*